La vendita allo scoperto per Corbus Pharmaceuticals dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Corbus Pharmaceuticals. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Corbus Pharmaceuticals (NASDAQ:CRBP) Azioni, Report sulle vendite allo scoperto

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals Holdings Inc

News

Guidance

SANW

S&W Seed Expects High End Of Range To Be At Adjusted EBITDA Breakeven For The Rest Of FY25

Ambarella Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) shares are soaring in Tuesday&#8217;s after-hours session on the heels of the company&#8217;s third-quarter financial results. Here&#8217;s a look at the key <a href="https://www.benzinga.com/pressreleases/24/11/g42200722/ambarella-inc-announces-third-quarter-fiscal-year-2025-financial-results">highlights from the quarter</a>.
What Happened: Ambarella reported third-quarter revenue of $82.65 million, beating analyst estimates of $79.03 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported third-quarter adjusted earnings of 11 cents per share, beating estimates of four cents per share.
&#8220;Company-specific factors are more than offsetting broad market weakness, and we are reporting 30% sequential revenue growth in fiscal Q3, above the high-end of our guidance range, with strength led again by our customers&#8217; new products, especially those incorporating our higher priced AI inference processors,&#8221; said Fermi Wang, president and CEO of Ambarella.
&#8220;Edge AI revenue represented about&nbsp;70%&nbsp;of our total revenue, establishing a new record level, and this momentum is expected to enable growth in both our IoT and Auto markets in F2025 and F2026.&#8221;
Ambarella ended the quarter with $226.5 million in cash, cash equivalents and marketable debt securities, up from $222.3 million at the end of the prior year&#8217;s quarter.
See Also: <a href="https://www.benzinga.com/news/earnings/24/11/42201885/dell-technologies-shares-drop-after-q3-revenue-misses-estimates-details">Dell Technologies Shares Drop After Q3 Revenue Misses Estimates: Details</a>
What&#8217;s Next: Ambarella expects fourth-quarter revenue to be between $76 million and $80 million. Fourth-quarter gross margin is expected to be between 61.5% and 63%, and operating expenses are expected to range between $49 million to $52 million.
&#8220;With the anticipated revenue growth, we intend to drive positive operating leverage and build upon our 15 consecutive fiscal years of positive free-cash-flow,&#8221; Ambarella&#8217;s CEO added.
AMBA Price Action: Ambarella shares were up 22.42% in extended trading at $83.75 at the time of publication Tuesday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Earnings

After-Hours Center

Movers

Tech

AMBA

Ambarella Stock Soars In After-Hours Trading Tuesday: What's Going On?

S&W Files Q1 2025 10-Q; Says Financial Results Filed Are In Line With Preliminary Financial Results Previously Released

The parties anticipate closing the transaction on December 2, 2024. Upon completion of the transaction, New TechTarget's shares of common stock are expected trade on Nasdaq under the stock ticker symbol "TTGT".
 &nbsp;

TTGT

TechTarget Shareholders Approve Previously Announced Transaction For Combination With Informa Tech's Digital Businesses

A scathing Senate report released on Tuesday has criticized major U.S. airlines for profiting billions from seat selection fees, raising questions about transparency <a href="https://www.benzinga.com/topic/airlines">and consumer fairness. </a>
The Permanent Subcommittee on Investigations revealed that from 2018 to 2023, carriers like American Airlines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>), Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>), and United Airlines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) generated $12.4 billion in fees for seat upgrades and preferred placements, <a href="https://www.cnbc.com/2024/11/26/senate-report-slams-airlines-for-raking-in-billions-in-seat-fees.html" target="_blank" rel="noreferrer noopener">CNBC</a> reports.
As travelers face rising costs for options like extra legroom or aisle seats, the report highlighted how these fees, initially marketed as optional, have become a significant revenue stream. CNBC reports that United alone earned $1.3 billion from seating fees last year—outpacing its checked bag-fee revenue for the first time.
Budget carriers like Spirit Airlines (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SAVEQ#OTC">SAVEQ</a>) and Frontier Airlines also came under fire. They incentivize gate agents to enforce bag size policies, sometimes at the expense of passenger experience.
Also Read: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42198763/fed-minutes-reveal-confidence-in-inflation-reduction-yet-flag-divergent-views-on-interest-rate-path-ahead">Fed Minutes Reveal &#8216;Confidence&#8217; In Inflation Reduction, Yet Flag Divergent Views On Interest Rate Path Ahead</a>
Airlines for America, the industry's trade group, defended the fees, stating the competitive landscape allows passengers to pay for what they value. However, consumer advocates argue these practices burden travelers while masking true ticket costs, according to CNBC.
Budget airlines have faced additional scrutiny. Spirit Airlines awarded its CEO a $3.8 million retention bonus just days before filing for Chapter 11 bankruptcy. This financial maneuver came as the company sought to restructure debt while continuing operations <a href="https://www.benzinga.com/general/travel/24/11/42127269/spirit-airlines-ceo-gets-3-8-million-bonus-1-week-before-company-files-bankruptcy">under bankruptcy protection.</a>
Sen. Richard Blumenthal (D-CT), chair of the subcommittee, announced that airline executives will testify at a Dec. 4 hearing titled "The Sky's the Limit—New Revelations About Airline Fees."
The Biden administration passed various <a href="https://www.transportation.gov/briefing-room/biden-harris-administration-announces-final-rule-requiring-automatic-refunds-airline">protections</a> for airline consumers (i.e., automatic refunds after canceled flights).
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/24/11/42198583/will-trump-lead-us-into-trade-war-with-mexico-president-claudia-sheinbaum-rebukes-threats">Will Trump Lead US Into Trade War With Mexico? President Claudia Sheinbaum Rebukes Threats</a></li>
</ul>
Photo: Shutterstock

Government

Travel

SAVEQ

Senate Targets Airlines Over $12.4 Billion Seat Fees Amid Mounting Scrutiny

Workday, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) reported its third-quarter results after Tuesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/11/n42200629/workday-announces-fiscal-2025-third-quarter-financial-results">details from the report. </a>
The Details: Workday reported quarterly earnings of $1.89 per share, which beat the analyst consensus estimate of $1.76. Quarterly revenue came in at $2.16 billion which beat the consensus estimate of $2.13 billion and is an increase over sales of $1.87 billion from the same period last year.
<ul>
<li>Subscription revenues were $1.959 billion, up 15.8% year-over-year.</li>
<li>The 12-month subscription revenue backlog was $6.98 billion, up 15.3% from the same period last year.</li>
<li>Total subscription revenue backlog was $22.19 billion, increasing 20.3% year-over-year.</li>
<li>Operating cash flows were $406 million compared to $451 million in the prior year. </li>
<li>Free cash flows were $359 million compared to $391 million in the prior year.</li>
</ul>
Read Next: <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a>
&#8220;Workday&#8217;s solid performance in Q3 reflects the trust our customers place in us across industries, the global momentum around our AI-driven innovations, and the strength of our partner ecosystem,&#8221; said Carl Eschenbach, CEO of Workday. 
&#8220;Organizations are increasingly consolidating on the Workday platform to reduce total cost of ownership, simplify their operations, and to unlock the power of our best-in-class AI solutions. Workday gives them the ultimate advantage — and that positions our business for long-term success,&#8221; Eschenbach added.
Outlook:&nbsp;Workday revised its fiscal 2025 subscription revenue outlook lower from between $7.7 billion and $7.725 billion to $7.703 billion, representing growth of 17%. 
WDAY Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Workday shares are down 10.32% after-hours at $242 at the time of publication Tuesday. 
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Photo: Shutterstock

Personal Finance

WDAY

Workday Stock Slides After Q3 Results Beat Expectations, FY Subscription Revenue Guidance Revised Lower

X Financial Reports Q3 EPADS Of $1.27, Sales Of $225.5M, Both Up From Prior Year

3D Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) announced its Q3 earnings on Tuesday, November 26, 2024 at 04:15 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
3D Sys missed estimated earnings by -33.0%, reporting an EPS of $-0.12 versus an estimate of $-0.09.
Revenue was down $10.85 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
In the previous quarter, the company missed on EPS by $0.1, resulting in a 8.0% drop change in the share price the following day.
Here's a look at 3D Sys's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.04</td>
<td>-0.08</td>
<td>-0.01</td>
<td>-0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.14</td>
<td>-0.17</td>
<td>-0.11</td>
<td>0.01</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>116.45M</td>
<td>107.63M</td>
<td>126.63M</td>
<td>129.97M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>113.25M</td>
<td>102.91M</td>
<td>114.85M</td>
<td>123.79M</td>
</tr>
</tbody>
</table>

To track all earnings releases for 3D Sys <a href="https://www.benzinga.com/quote/DDD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Summary: 3D Sys Q3

Autodesk Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) reported third-quarter financial results after the market close on Tuesday. Here&#8217;s a <a href="https://www.benzinga.com/pressreleases/24/11/n42200628/autodesk-inc-announces-fiscal-2025-third-quarter-results">rundown of the report</a>.
<ul>
<li>Q3 Revenue: $1.57 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $1.56 billion</li>
</ul>
<ul>
<li>Q3 Adjusted EPS: $2.17, versus estimates of $2.12</li>
</ul>
Total revenue was up 11% year-over-year. Total billings increased 28% year-over-year to $1.54 billion. Cash flow from operations was $209 million, while free cash flow totaled $199 million in the quarter. The company ended the period with $1.44 billion in cash and cash equivalents. 
&#8220;Autodesk is leading the industry in modernizing its go-to-market motion. These initiatives enable us to build larger and more durable direct relationships with our customers and to serve them more efficiently. We have already seen significant benefits from these optimization initiatives and there&#8217;s more to come in the next phase,&#8221; said&nbsp;Andrew Anagnost, president and CEO of Autodesk.
See Also: <a href="https://www.benzinga.com/24/11/42199235/mrbeasts-game-show-hits-prime-video-on-dec-19-one-week-ahead-of-netflixs-second-season-of-squid-game">Amazon Prime Vs. Netflix: MrBeast Game Show Arrives Dec. 19, &#8216;Squid Game&#8217; Season 2 Drops 1 Week Later</a>
Outlook: Autodesk expects fourth-quarter revenue to be in the range of $1.623 billion to $1.638 billion versus estimates of $1.621 billion. The company sees fourth-quarter earnings of $2.10 to $2.16 per share versus estimates of $2.12 per share. 
Autodesk anticipates full-year revenue of $6.12 billion to $6.13 billion versus estimates of $6.11 billion. The company expects full-year earnings to be between $8.29 and $8.35 per share versus estimates of $8.27 per share. 
Autodesk announced the appointment of Janesh Moorjani&nbsp;as the company&#8217;s CFO, effective Dec. 16. Management will hold a conference call to further discuss the quarter with analysts and investors at 5 p.m. ET.
ADSK Price Action: Autodesk shares were down 8.53% after hours, trading at $290.83 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Courtesy of Autodesk.

Offerings

ADSK

Autodesk Stock Slides On Q3 Earnings: Key Details From Quarter

Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) announced its Q3 earnings on Tuesday, November 26, 2024 at 04:01 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Workday beat estimated earnings by 7.000000000000001%, reporting an EPS of $1.89 versus an estimate of $1.76.
Revenue was up $294.00 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
Last quarter the company beat on EPS by $0.1 which was followed by a 12.0% increase in the share price the next day.
Here's a look at Workday's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.65</td>
<td>1.58</td>
<td>1.47</td>
<td>1.41</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.75</td>
<td>1.74</td>
<td>1.57</td>
<td>1.53</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>2.07B</td>
<td>1.97B</td>
<td>1.92B</td>
<td>1.85B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>2.08B</td>
<td>1.99B</td>
<td>1.92B</td>
<td>1.87B</td>
</tr>
</tbody>
</table>

To track all earnings releases for Workday <a href="https://www.benzinga.com/quote/WDAY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Workday Earnings Review: Q3 Summary

President-elect Donald Trump's latest tariff proposal could represent a potential economic earthquake, with economists already forecasting significant fallout for trade flows, exchange <a href="https://www.benzinga.com/etfs/currency-etfs/24/11/42190765/trumps-tariff-threats-slam-mexican-peso-canadian-dollar-only-the-beginning-of-a-sorely-needed-repricing-expert-warns">rates and consumer prices.</a>
On Monday, Trump announced plans to impose a 25% tariff on all imports from Mexico and Canada, blaming these nations for failing to curb drug trafficking and illegal immigration. Additional, he pledged a 10% hike on Chinese tariffs. 
Mexico, Canada, and China collectively make up 43% of U.S. goods imports, with shares of 15.4%, 13.6%, and 13.9%, respectively, according to Goldman Sachs. 
<h3 class="wp-block-heading">Goldman Sachs: Tariffs Could Rattle Global Markets</h3>
Goldman Sachs analysts were quick to assess the broader economic implications of Trump's tariff rhetoric. 
Isabella Rosenberg, a Goldman Sachs forex analyst, said the proposed 25% tariff on Mexican and Canadian imports would represent a significant economic shock for both the loonie and the peso.
"If tariffs were to rise to 25%, the estimated impact to USD/CAD and USD/MXN would be about 13% and 17%, respectively," she said in a note to clients on Tuesday.
On Tuesday, the Mexican peso weakened by 1.9%, while the Canadian dollar – as tracked by the Invesco CurrencyShares Canadian Dollar Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXC#NYSE">FXC</a>) – fell by 0.6%. 
Tariffs at the levels proposed by Trump would disrupt supply chains and amplify costs, Rosenberg said. 
The analyst said she expects that a renegotiation of United States-Mexico-Canada Agreement (USMCA) – which replaced the previous North America Free Trade Agreement (NAFTA) – will likely take place next year.
&#8220;The USMCA is up for review and renewal in 2026, and it appears likely that this will involve renegotiating some aspects of the Agreement,&#8221; she wrote. Such uncertainty will keep the Canadian dollar under pressure in 2025, according to her view.
Joseph Briggs, an economist at Goldman, said: "We expect that the incoming Trump administration will impose higher tariffs on imports from China as well as auto imports from Europe and Mexico shortly after his inauguration in January."
Briggs added that the tariffs would likely affect economic data even before they're enacted, citing heightened policy uncertainty and ripple effects across currency markets.
<h3 class="wp-block-heading">$300 Billion In Government Revenue, But At Cost Of Higher Inflation</h3>
If fully rolled out, the tariffs would generate nearly $300 billion in annual revenue for the U.S. government, equivalent to about 1% of GDP, according to Goldman's calculations.
Yet the direct effects of tariffs don't stop at border disputes — they also trickle down to the wallets of everyday Americans.
Goldman Sachs estimates the effective tariff rate in the U.S. would rise by 8.6%, leading to a 0.9% increase in core PCE (Personal Consumption Expenditures) prices.
For context, this inflationary impact is three times larger than the effect of previous tariffs under Trump's first administration, such as those targeting China and auto imports.
<h3 class="wp-block-heading">Bottom Line: Trade Tensions Are Back</h3>
Trump's latest trade salvo reintroduces significant tension to global markets, evoking comparisons to his first term's tariff battles. 
The potential 25% tariff on Mexico and Canada has economists and investors bracing for wide-ranging effects, from inflation and exchange rate volatility to supply chain disruption and consumer pain.
While Trump's hardline tactics often double as negotiating strategies, the sheer scale of this proposal ensures that its reverberations will be felt long before Jan. 20.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/24/11/42198583/will-trump-lead-us-into-trade-war-with-mexico-president-claudia-sheinbaum-rebukes-threats">Will Trump Lead US Into Trade War With Mexico? President Claudia Sheinbaum Rebukes Threats</a></li>
</ul>

Analyst Color

Asia

Latin America

Macro Economic Events

Emerging Markets

Currency ETFs

Politics

Forex

Global

Economics

Markets

ETFs

Goldman Sachs Expects Major Selloffs In Canadian Dollar, Mexican Peso, Says Trump Tariffs Threaten USMCA Agreement

The Corporation anticipates using the net proceeds of the Offering for working capital related to its recently announced intention to expand assembly operations into Malaysia and for other corporate purposes. It is anticipated that the Offering will close on or about December 3, 2024.

POET

POET Technologies Plans $25M Registered Direct Offering

Ambarella (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.04 by 175 percent. This is a 139.29 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $82.65 million which beat the analyst consensus estimate of $79.03 million by 4.58 percent. This is a 63.36 percent increase over sales of $50.59 million the same period last year.

Earnings Beats

CORRECTION: Ambarella Q3 Adj $0.11 Beats $0.04 Estimate, Sales $82.65M Beat $79.03M Estimate

Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) reported its Q3 earnings results on Tuesday, November 26, 2024 at 04:00 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Autodesk beat estimated earnings by 2.0%, reporting an EPS of $2.17 versus an estimate of $2.12.
Revenue was up $156.00 million from the same period last year.
<h3>Historical Earnings Summary</h3>
During the previous quarter, the company beat on EPS by $0.15, leading to a 0.0% increase share price change the next day.
Here's a look at Autodesk's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2</td>
<td>1.77</td>
<td>1.95</td>
<td>1.99</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.15</td>
<td>1.87</td>
<td>2.09</td>
<td>2.07</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.48B</td>
<td>1.39B</td>
<td>1.43B</td>
<td>1.39B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.50B</td>
<td>1.42B</td>
<td>1.47B</td>
<td>1.41B</td>
</tr>
</tbody>
</table>

To track all earnings releases for Autodesk <a href="https://www.benzinga.com/quote/ADSK/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Autodesk: Q3 Earnings Insights

A group of 14 Democratic lawmakers is urging President Joe Biden to expand his marijuana pardons and deprioritize federal cannabis prosecutions before the end of his term. 
In a letter addressed to Biden and VP Kamala Harris, Senators Elizabeth Warren (D-MA), Barbara Lee (D-CA), Bernie Sanders (I-VT) as well as Reps. Earl Blumenauer (D-OR) and Ilhan Omar (D-MN), along with nine more colleagues applauded Biden for getting the ball rolling on cannabis rescheduling but that more needs to be done before he leaves office.
<h2 class="wp-block-heading">Rescheduling Cannabis Is Not Enough</h2>
"Moving marijuana to Schedule III represents progress, and we urge the Drug Enforcement Administration to complete that process as soon as possible. But it will not end federal criminalization, resolve its harms, or meaningfully address the gap between federal and state cannabis policy," the lawmakers said in the letter, which was first <a href="https://www.rollingstone.com/politics/politics-features/dems-biden-decriminalize-weed-trump-1235181464/">reported</a> by Rolling Stone. "Possession and use of recreational marijuana—and much state-legal medical marijuana—will continue to be a violation of federal law."
Read Also: <a href="https://www.benzinga.com/news/legal/24/11/42177984/joe-biden-how-about-pardoning-non-violent-cannabis-prisoners-along-with-those-thanksgiving-turkeys">Joe Biden, How About Pardoning Non-Violent Cannabis Prisoners Along With Those Thanksgiving Turkeys?</a>
While lawmakers credited Biden for pardoning individuals with federal marijuana possession convictions, they rightly pointed out that these measures have resulted in no prison releases.
"President Biden should issue broader clemency — including another round of pardons and commutations to reduce sentences or end terms of incarceration — for individuals convicted of other cannabis-related offenses," the lawmakers wrote. "Additionally, the President should again urge state governors to expand marijuana clemency and decriminalize low-level marijuana conduct under state law."
The congress members urged the Biden administration to grant broader clemency, including additional pardons and sentence commutations; they encouraged governors to extend similar pardons at the state level.
<h2 class="wp-block-heading">Federal Convictions Still Persist</h2>
The second part of their request focused on issuing a memorandum to deprioritize federal enforcement against state-legal cannabis activity. Despite declining federal cannabis prosecutions due to state-level legalizations, the lawmakers noted that the threat of federal convictions persists. 
Then there are the racial disparities in enforcement, the letter pointed out and further cited recent incidents where Customs and Border Protection (CBP) seized state-legal cannabis, including cases in New Mexico.
Signatories also include Cory Booker (D-NJ), Ron Wyden (D-OR), John Hickenlooper (D-CO), Kirsten Gillibrand (D-NY) and Ben Ray Lujan (D-NM) as well as Reps. Jan Schakowsky (D-IL), Dina Titus (D-NV), Jim McGovern (D-MA) and Eleanor Holmes Norton (D-DC).
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/42087262/president-biden-people-are-still-in-jail-for-marijuana-despite-your-promise-cannabis-clemency-advocates-call-for-change">President Biden, People Are Still In Jail For Marijuana Despite Your Promise, Cannabis Clemency Advocates Call For Change</a></li>
</ul>
Photo: Benzinga edit Adam Schultz on Wikimedia Commons and David Smart on Shutterstock<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" target="_blank" rel="noreferrer noopener"></a>

Cannabis

Legal

Elizabeth Warren, Bernie Sanders & 12 Congress Members To Biden: Issue Clemency And Pardons For Cannabis Prisoners

urban-gro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) ("urban-gro" or the "Company"), an integrated professional services and Design-Build firm offering solutions to the Controlled Environment Agriculture ("CEA") and commercial sectors, today announced the launch of its new Processing and Extraction Division. Further expanding urban-gro's sector offering, this strategic expansion driven by client demand, delivers cutting-edge solutions designed to optimize cannabis facilities for post-harvest operations.
The Processing and Extraction Division addresses the growing need for advanced post-harvest services and access to high-quality processing equipment. By seamlessly integrating design, engineering, and construction services with equipment provisioning, this division will ensure that facilities meet the highest industry standards and regulatory requirements. Through urban-gro's engineering and architectural services, it designs and builds rated extraction spaces, C1D1/C1D2 hazardous environments, dry rooms, and post-processing areas, with an emphasis on the mechanical and HVAC systems that are critical for facility safety and compliance. urban-gro's construction services ensure that all lab build-outs comply with fire codes and other cannabis-specific regulations, providing both safety and regulatory adherence for high-stakes extraction and post-processing operations.

UGRO

urban-gro Announces The Launch Of Its New Processing And Extraction Division, Expanding urban-gro's Sector Offering; Strategic Expansion Driven By Client Demand, Delivers Solutions Designed To Optimize Cannabis Facilities For Post-Harvest Operations

Econ #s

USA API Weekly Crude Oil Stock A Draw Of 5.935M Barrels Vs A Build Of 0.250M Barrels Est.; Build Of 4.753M Barrels Prior

The Q1 earnings report for Nutanix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) was released on Tuesday, November 26, 2024 at 04:01 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Nutanix beat estimated earnings by 31.0%, reporting an EPS of $0.42 versus an estimate of $0.32.
Revenue was up $79.90 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
The company beat on EPS by $0.07 in the last quarter, resulting in a 20.0% increase share price change the following day.
Here's a look at Nutanix's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.20</td>
<td>0.16</td>
<td>0.29</td>
<td>0.17</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.27</td>
<td>0.28</td>
<td>0.46</td>
<td>0.29</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>536.94M</td>
<td>516.18M</td>
<td>551.34M</td>
<td>501.32M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>547.95M</td>
<td>524.58M</td>
<td>565.23M</td>
<td>511.05M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Nutanix <a href="https://www.benzinga.com/quote/NTNX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NTNX

Nutanix: Q1 Earnings Insights

Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) reported its Q3 earnings results on Tuesday, November 26, 2024 at 04:00 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Autodesk beat estimated earnings by 2.0%, reporting an EPS of $2.17 versus an estimate of $2.12.
Revenue was up $156.00 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
The company beat on EPS by $0.15 in the previous quarter, leading to a 0.0% increase share price change the next day.
Here's a look at Autodesk's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2</td>
<td>1.77</td>
<td>1.95</td>
<td>1.99</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.15</td>
<td>1.87</td>
<td>2.09</td>
<td>2.07</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.48B</td>
<td>1.39B</td>
<td>1.43B</td>
<td>1.39B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.50B</td>
<td>1.42B</td>
<td>1.47B</td>
<td>1.41B</td>
</tr>
</tbody>
</table>

To track all earnings releases for Autodesk <a href="https://www.benzinga.com/quote/ADSK/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Breakdown: Autodesk Q3

Nutanix Sees Q2 Revenue $635M-$645M.

Corbus Pharmaceuticals (CRBP) presents new pre-clinical data at Obesity Week 2024 further characterizing CRB-913, its highly peripherally restricte...

Corbus Pharmaceuticals presents new CRB-913 pre-clinical data at Obesity Week

Andres Y. Maldonado, an analyst from H.C. Wainwright, maintained the Buy rating on Corbus Pharmaceuticals (CRBP – Research Report). The associated ...

Corbus Pharmaceuticals' CRB-913: A Promising and Safer Alternative in Obesity Treatment with a Buy Rating

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on CRBP stock, giving a Buy rating yesterday. Graig Suvannavejh has...

Buy Rating for Corbus Pharmaceuticals on Promising CRB-913 Obesity Treatment and Favorable Risk/Reward Scenario

As of September 30, 2024, the Company had $159.4 million in cash, cash equivalents and investments on hand, which is expected to fund operations th...

Corbus Pharmaceuticals expects cash to fund operations through 3Q27

"We continue to make steady and significant progress across our pipeline," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "We expect t...

Corbus Pharmaceuticals reports Q3 EPS ($1.15), consensus (95c)

An update from Corbus Pharmaceuticals ( ($CRBP) ) is now available. Corbus Pharmaceuticals, an oncology and obesity-focused company, reported a net...

Corbus Pharmaceuticals Reports Q3 2024 Financial Results

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

H.C. Wainwright analyst Andres Maldonado lowered the firm's price target on Corbus Pharmaceuticals (CRBP) to $75 from $80 and keeps a Buy rating on...

Corbus Pharmaceuticals price target lowered to $75 from $80 at H.C. Wainwright

In a report released on November 7, Brian Abrahams from RBC Capital maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report), wit...

Corbus Pharmaceuticals (CRBP) Receives a Buy from RBC Capital

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

ALKS

APLS

CRBP

DERM

ELAB

NKTR

NONOF

RPRX

SNYNF

TKPHF

VKTX

VRCA

VRNA

Press Releases

Corbus Pharmaceuticals to Present at the 2024 Cantor Global Health Conference

Transforming Oncology: Stocks to Watch in the Oncology Sector

Transforming Cancer Therapy Stocks to Watch In The Oncology Sector

Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024

Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update

Health Care

Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference

Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference

ACON

ATNM

OSTX

PBYI

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Corbus Pharmaceuticals

Vendite allo scoperto

Corbus Pharmaceuticals (NASDAQ:CRBP) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO